Hepatosplenic T cell lymphoma in inflammatory bowel disease

Shale, Matthew; Kanfer, Edward; Panaccione, Remo; Ghosh, Subrata

doi:10.1136/gut.2008.163279

Cited by 143 publications

(83 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, a cluster of cases of a rare, particularly aggressive lymphoma, hepatosplenic T-cell lymphoma, has been reported in CD patients treated with concomitant azathioprine and infl iximab ( 177 -179 ). Th is particular lymphoma has only rarely been reported and some cases were associated with azathioprine monotherapy ( 180 ). It usually presents in younger male patients and has an almost universally fatal outcome.…”

Section: Infl Iximabmentioning

confidence: 99%

“…However, experience with the thiopurines over the last four decades indicates that there is not an increased risk of the development of solid tumors (as discussed above) ( 201 ) or overall mortality ( 200,238 ). Conversely, a recent meta-analysis of six cohort studies calculated a fourfold increased risk of lymphoma among IBD patients treated with thiopurines, but it remains unclear whether this risk was due to the medications themselves or due to the underlying disease ( 176,180,239 ).…”

Section: The Patient With Severe Colitis Refractory To Maximal Oral Tmentioning

confidence: 99%

See 1 more Smart Citation

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Kornbluth

Sachar

2010

American Journal of Gastroenterology

1,144

977

View full text Add to dashboard Cite

Guidelines for clinical practice are aimed to indicate preferred approaches to medical problems as established by scientifi cally valid research. Double-blind placebo controlled studies are preferable, but compassionate-use reports and expert review articles are used in a thorough review of the literature conducted through Medline with the National Library of Medicine. When only data that will not withstand objective scrutiny are available, a recommendation is identifi ed as a consensus of experts. Guidelines are applicable to all physicians who address the subject regardless of specialty training or interests and are aimed to indicate the preferable but not necessarily the only acceptable approach to a specifi c problem. Guidelines are intended to be fl exible and must be distinguished from standards of care, which are infl exible and rarely violated. Given the wide range of specifi cs in any healthcare problem, the physician must always choose the course best suited to the individual patient and the variables in existence at the moment of decision. Guidelines are developed under the auspices of the American College of Gastroenterology and its Practice Parameters Committee and approved by the board of trustees. Each has been intensely reviewed and revised by the Committee, other experts in the fi eld, physicians who will use them, and specialists in the science of decision analysis. The recommendations of each guideline are therefore considered valid at the time of composition based on the data available. New developments in medical research and practice pertinent to each guideline will be reviewed at a time established and indicated at publication to assure continued validity. The recommendations made are based on the level of evidence found. Grade A recommendations imply that there is consistent level 1 evidence (randomized controlled trials), grade B indicates that the evidence would be level 2 or 3, which are cohort studies or case -control studies. Grade C recommendations are based on level 4 studies, meaning case series or poor-quality cohort studies, and grade D recommendations are based on level 5 evidence, meaning expert opinion.

show abstract

Section: Infl Iximabmentioning

confidence: 99%

Section: The Patient With Severe Colitis Refractory To Maximal Oral Tmentioning

confidence: 99%

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Kornbluth

Sachar

2010

American Journal of Gastroenterology

1,144

977

View full text Add to dashboard Cite

show abstract

“…However, the risk of HSTCL does seem to be related to thiopurine and anti-TNF therapy. DNA damage specific to chromosome 7 has been seen in a dose dependent manner with thiopurine agents (Piccin et al, 2010) and inhibition of TNF may result in decreased effectiveness of immune surveillance eliminating cells with aberrant abnormal chromosomal pattern (Shale et al, 2008).…”

Section: Hstcl In Ibdmentioning

confidence: 99%

Evaluating Lymphoma Risk in Inflammatory Bowel Disease

Prasad¹

2012

New Advances in the Basic and Clinical Gastroenterology

View full text Add to dashboard Cite

“…Although the majority of these cases seem to have developed de novo, approximately a third have been associated with immunosuppressive therapy for various reasons, mostly for organ transplantations and other conditions that require immune-modifying agents; most cases involving thiopurines [5,23,24]. Several immunocompromised conditions described in the literature include renal transplantation, heart transplantation, Hodgkin lymphoma, acute myelogenous leukemia, inflammatory bowel disease and malaria infection [4][5][6]13,[23][24][25][26][27][28][29][30][31][32].…”

Section: Associated Conditionsmentioning

confidence: 99%